Researchers Are Studying Whether Paxlovid Can Treat Long COVID
Months after catching COVID-19 in December 2021, Lavanya Visvabharathy was still testing positive on antigen tests and suffering from symptoms including headaches and intense fatigue. So Visvabharathy, a research assistant professor of neurology at the Northwestern University Feinberg School of Medicine who has studied Long COVID since 2020, decided to conduct an experiment on herself. She asked her doctor to prescribe her Paxlovid, an antiviral therapy that can treat COVID-19 by inhibiting replication of the virus that causes it. Paxlovid is meant to keep high-risk patients with acute COVID-19 from developing severe disea...
Source: TIME: Health - November 29, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
AAP Issues Guidelines to Combat Rise in Respiratory Illness AAP Issues Guidelines to Combat Rise in Respiratory Illness
Recommendations to manage an unprecedented wave of infections include extra doses of antiviral therapy for children at high risk.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 21, 2022 Category: Infectious Diseases Tags: Pediatrics News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Walgreens, DoorDash, Uber partner on Paxlovid delivery in underserved areas
The collaboration to deliver the oral antiviral therapy for COVID-19 will launch in the coming weeks. (Source: mobihealthnews)
Source: mobihealthnews - October 26, 2022 Category: Information Technology Source Type: news
Antiviral Therapy Improves Survival After Liver Cancer Surgery Antiviral Therapy Improves Survival After Liver Cancer Surgery
The analysis focused on elderly patients after hepatectomy for hepatitis B virus –related hepatocellular carcinoma. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 20, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Paxlovid Doesn ’t Work for Healthier Patients, Pfizer Says
Pfizer Inc. plans to stop enrollment in a study of its COVID-19 drug in patients who aren’t at high risk of severe disease after the pill didn’t help alleviate their symptoms, a major setback for broader use of the treatment. The New York-based drugmaker said Tuesday that it would stop adding new participants to a highly anticipated study testing Paxlovid in a broader population of COVID patients who are at low risk of hospitalization and death. The decision comes after the study failed to demonstrate that the drug reduced COVID symptoms among relatively healthy patients and wasn’t able to show a statisti...
Source: TIME: Health - June 15, 2022 Category: Consumer Health News Authors: Riley Griffin and Madison Muller / Bloomberg Tags: Uncategorized COVID-19 News Desk wire Source Type: news
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Tomato concentrate could help reduce chronic intestinal inflammation associated with HIV
New UCLA-led research in mice suggests that adding a certain type of tomato concentrate to the diet can reduce the intestinal inflammation that is associated with HIV. Left untreated, intestinal inflammation can accelerate arterial disease, which in turn can lead to heart attack and stroke.The findings provide clues to how the altered intestinal tract affects disease-causing inflammation in people with chronic HIV infection, suggesting that targeting the inflamed intestinal wall may be a novel way to prevent the systemic inflammation that persists even when antiviral therapy is effective in controlling a person ’s HIV.Th...
Source: UCLA Newsroom: Health Sciences - January 11, 2022 Category: Universities & Medical Training Source Type: news
Why We Are Developing a Patent-Free COVID Antiviral Therapy Why We Are Developing a Patent-Free COVID Antiviral Therapy
During global health crises such as pandemics, drug discovery should be publicly funded and open, with no research secrets locked away.Knowable Magazine (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 29, 2021 Category: Intensive Care Tags: Infectious Diseases Commentary Source Type: news
Synthetic SARS-CoV-2 could be used as antiviral therapy for COVID-19: Study
The cell is then tricked into reproducing the virus's genetic material and packaging it into virions, particles which burst from the cell and go off to infect other cells. (Source: The Economic Times)
Source: The Economic Times - July 13, 2021 Category: Consumer Health News Source Type: news
India's Hetero says COVID-19 drug reduces hospitalisations in late-stage trial
Molnupiravir is an antiviral therapy Merck& Co is developing with Ridgeback Biotherapeutics for the treatment of non-hospitalised COVID-19 patients. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 9, 2021 Category: Pharmaceuticals Source Type: news
Liver Transplant Outcomes Improving for US Patients With HIV/HCV Liver Transplant Outcomes Improving for US Patients With HIV/HCV
Hepatitis C virus (HCV) infection no longer confers worse patient survival in the era of direct-acting antiviral therapy, but the population remains underserved.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 28, 2021 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news
City of Hope and Griffith University develop direct-acting antiviral to treat COVID-19
(City of Hope) An international team of scientists have developed an experimental direct-acting antiviral therapy to treat COVID-19. Traditional antivirals reduce symptoms and help people recover earlier. This next-generation antiviral approach used gene-silencing RNA technology called siRNA (small-interfering RNA) to attack the virus' genome directly, which stops the virus from replicating, as well as lipid nanoparticles designed at Griffith University and City of Hope to deliver the siRNA to the lungs, the critical site of infection. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 18, 2021 Category: Biology Source Type: news